Status:
COMPLETED
Extension Safety and Immunogenicity Study of GPNV-001
Lead Sponsor:
GPN Vaccines
Conditions:
Pneumococcal Infections
Eligibility:
All Genders
18-69 years
Phase:
PHASE1
PHASE2
Brief Summary
A 6 and 12 month safety and immunogenicity study of participants in study GPNV-001, a novel whole-cell pneumococcal vaccine.
Detailed Description
A 6 and 12 month safety and immunogenicity study of participants in study GPNV-001, a novel whole-cell pneumococcal vaccine. Up to 20 participants per cohort will be invited.
Eligibility Criteria
Inclusion
- Completion of study GPNV-001 as per protocol with no significant deviations.
- Has provided written informed consent.
Exclusion
- Potential participants will be excluded if they have received a pneumococcal vaccine since the end of study visit for study GPNV-001
- A potential participant has had an episode of pneumonia since completing Study GPNV-001
Key Trial Info
Start Date :
July 17 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 30 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05982314
Start Date
July 17 2023
End Date
August 30 2024
Last Update
December 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Adelaide
Adelaide, South Australia, Australia, 5005